An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Anavex Life Sciences

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: ANAVEX2-73

Study type: Interventional

Funder types: Industry

Identifiers

NCT02756858

ANAVEX2-73-003

Details and patient eligibility

About

This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.

Enrollment: 21 patients

Sex: All

Ages: 55 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previous exposure to ANAVEX2-73 via participation in Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)

Exclusion criteria

• Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

ANAVEX2-73 Oral as assigned in ANAVEX2-73-002

Experimental group

Treatment:

Drug: ANAVEX2-73